Melanoma refers to a type of skin cancer that is primarily caused by exposure to ultraviolet light (UV). They represent only 1% of all skin cancers. However, cancer-related death as a result of melanoma is a significant cause of concern. If not detected or treated early, melanoma can turn into a metastatic disease. Unresectable melanoma or metastatic melanoma is considered an aggressive form of cancer that can be life-threatening. This indicates the urgent need for clinical research efforts to introduce effective treatment options for patients suffering from unresectable melanoma.
The Unresectable Melanoma Drug Pipeline Report by Expert Market Research gives comprehensive insights into unresectable melanoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for unresectable melanoma. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from unresectable melanoma.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to unresectable melanoma are covered.
Historically, melanoma has posed a formidable challenge in the field of oncology, especially in its advanced stages. The introduction of targeted therapies and immune checkpoint inhibitors (ICIs) transformed the treatment landscape for the disease in the past decade. Further, the development of immune checkpoint inhibitors designed to target CTLA-4, PD-1, and PD-L1, among others, substantially enhanced the clinical outcomes for unresectable or advanced melanoma. However, significant challenges still remain such as the management of rare melanoma subtypes or the resistance to current treatments in certain cases.
In February 2024, Amtagvi (lifileucel) developed by Iovance Biotherapeutics Inc., the first cellular therapy for the treatment of unresectable or metastatic melanoma, received regulatory approval from the U.S. Food and Drug Administration. Moreover, the increasing research into identifying new genetic mutations and molecular pathways involved in the progression of unresectable melanoma that can be targeted with novel therapies is poised to lead to the expansion of the drug pipeline in the coming years.
This section of the report covers the analysis of unresectable melanoma drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for unresectable melanoma. There are around 70 drugs in phase II for unresectable melanoma.
The drug molecules categories covered under unresectable melanoma pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. The treatment for unresectable melanoma varies depending on the stage of the disease, the genetic mutations present in the tumor, the previous treatments, and the patient's health. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for unresectable melanoma.
The EMR report for the unresectable melanoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in unresectable melanoma clinical trials:
Major drugs currently in the pipeline are as follows:
The international, randomized, 2-arm study is designed to assess the safety and efficacy profile of IO102-IO103 in combination with pembrolizumab for the treatment of metastatic (advanced) melanoma or previously untreated unresectable melanoma. The trial, enrolling 400+ participants, is sponsored by IO Biotech and is currently under phase III.
The objective of the double-blind, randomized study is to compare the safety, efficacy, and immunogenicity of RPH-075 and Keytruda® in unresectable or metastatic skin melanoma patients. The trial is sponsored by R-Pharm and is currently under phase III.
Sponsored by Hoffmann-La Roche, this randomized, open-label, multicenter, phase II study aims to evaluate the pharmacokinetics (PK), and pharmacodynamics along with the efficacy and safety profile of two dose levels of the drug RO7247669 in around 80 participants with unresectable or metastatic melanoma.
This open-label Phase I study, sponsored by MacroGenics, is investigating the pharmacokinetics, pharmacodynamics, safety, tolerability, and preliminary antitumor activity of the biological candidate lorigerlimab in an estimated 162 patients with unresectable or metastatic neoplasms.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Unresectable Melanoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for unresectable melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within unresectable melanoma pipeline insights.
Global Cancer Therapeutics Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share